




RealRate

# MEDICINAL PRODUCTS 2023

Innospec INC  
Rank 18 of 55





# MEDICINAL PRODUCTS 2023

Innospec INC  
Rank 18 of 55



The relative strengths and weaknesses of Innospec INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Innospec INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 66% points. The greatest weakness of Innospec INC is the variable General and Administrative Expense, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 194%, being 42% points above the market average of 152%.

Input Variable	Value in 1000 USD
Assets, Current	872,600
Assets, Non-Current	52,400
General and Administrative Expense	1,737,700
Goodwill	403,800
Liabilities, Current	432,000
Liabilities, Non-Current	32,800
Other Assets	54,000
Other Compr. Net Income	-98,300
Other Expenses	51,600
Other Liabilities	98,500
Other Net Income	-2,700
Other Revenues	1,963,700
Property, Plant and Equipment, Net	220,900
Research and Development	38,700

Output Variable	Value in 1000 USD
Liabilities	563,300
Assets	1,603,700
Expenses	1,828,000
Revenues	1,963,700
Stockholders Equity	1,040,400
Net Income	133,000
Comprehensive Net Income	83,850
BaseVar	3,029,850
ECR before LimitedLiability	139%
Economic Capital Ratio	194%